{"prompt": "['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', '7.7.', 'Overdose', 'Overdose, as defined for this protocol, applies to protocol-required dosing of the investigational', 'product(s) (IPs) only. Therefore, for a drug to be subject to the overdose definition it must be', 'both required and an investigational drug. In this study the only required and investigational', 'drug is apremilast and the control arm drug (ie, placebo), hence overdose definition will apply to', 'only apremilast (or matching placebo). Other required or optional non-study drugs intended for', 'prophylaxis of certain side effects, etc, are excluded from this definition.', 'Overdose for this protocol, on a per dose basis, is defined as ingestion of 4 or more 30 mg', 'apremilast (or matching placebo) tablets in any 24-hour period, whether by accident or', 'intentionally. On a schedule or frequency basis, an overdose is defined as dosing more than 4', 'times during any 24-hour period.', 'Adverse Events associated with an overdose must be collected on the Adverse Events page of the', 'eCRF (see Section 10.1) for all overdosed subjects, but the overdose itself is not considered an', 'AE.', 'Confidential and Proprietary', '43', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', '8.', 'CONCOMITANT MEDICATIONS AND PROCEDURES', '8.1.', 'Permitted Concomitant Medications and Procedures', 'Subjects may take any medication that is not restricted by the protocol and would not be', 'expected to interfere with the conduct of the study or affect assessments. Chronic medication', 'should be dosed on a stable regimen.', 'All medications (prescription and non-prescription), treatments, and therapies taken by the', 'subject from signing the informed consent throughout their entire participation in the study,', 'including those initiated prior to signing the informed consent and continued through the start of', \"the study, must be recorded on the subject's source document and on the appropriate page of the\", 'eCRF. The dose, unit, frequency, route, indication, the date the medication was started, and the', 'date the medication was stopped (if not ongoing) must be recorded.', 'During the study, the initiation of new concomitant medications or a change of existing', 'concomitant medications may potentially indicate the presence of a new adverse event or the', 'worsening of an existing condition. If appropriate, such events should be recorded in the eCRF.', 'The following topical therapies will be permitted throughout the study:', 'Unmedicated skin moisturizers will be permitted for body lesions only.', '- Permitted skin moisturizers may not contain urea or salicylic acid.', '8.2.', 'Concomitant Medications Not Recommended', 'Co-administration of the strong cytochrome P450 3A4 (CYP3A4) enzyme inducer, rifampicin,', 'resulted in a reduction of systemic exposure of apremilast, which may result in a loss of efficacy', 'of apremilast. Therefore, the use of strong CYP3A4 enzyme inducers (eg, rifampicin,', \"phenobarbital, carbamazepine, phenytoin and St. John's Wort) with apremilast is not\", 'recommended during the study.', '8.3.', 'Prohibited Concomitant Medications and Procedures', 'The following psoriasis medications cannot be administered for the duration of the study.', 'Topical therapy', '- Topical therapy, unless otherwise specified in Section 8.1 (including, but not', 'limited to topical corticosteroids, retinoids or Vitamin D analog preparations,', 'tacrolimus, pimecrolimus, coal tar, anthralin/dithranol, or urea- and salicylic acid-', 'containing moisturizers)', 'Conventional systemic therapy', '- Conventional systemic therapy including but not limited to cyclosporine,', 'methotrexate, retinoids, mycophenolate, thioguanine, hydroxyurea, sirolimus,', 'sulfasalazine, azathioprine, fumaric acid esters, and corticosteroids', 'Biologic agents, including:', 'Confidential and Proprietary', '44', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', '- Adalimumab, etanercept, infliximab, or certolizumab pegol, ustekinumab,', 'secukinumab, ixekizumab, brodalumab, guselkumab, tildrakizumab', 'Phototherapy', '- Ultraviolet light B (UVB) or psoralens and long-wave ultraviolet radiation', '(PUVA)', 'Use of any investigational drug or device', 'Use of tanning booths, which may confound the ability to interpret data from the', 'study.', '8.4.', 'Required Concomitant Medications and Procedures', 'Not applicable.', 'Confidential and Proprietary', '45', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']\n\n###\n\n", "completion": "END"}